Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice

Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice

Abstract Aims Whether sodium‐glucose co‐transporter 2 inhibitors are effective for heart failure caused by ATTR‐CA (transthyretin cardiac amyloidosis) remains uncertain. The aim of this study is to investigate the cardiovascular prognosis in ATTR‐CA mice model with dapagliflozin treatment. Methods a...

Full description

Bibliographic Details
Main Authors: Zonglin Li, Fang Lv, Xin Wen, Chengcheng Guo, Li Li, Xiaoling Cai, Chu Lin, Mengqing Zhang, Wenjia Yang, Linong Ji
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:ESC Heart Failure
Subjects:
ATTR
Cardiovascular prognosis
Dapagliflozin
Heart failure
Transthyretin cardiac amyloidosis
Online Access:https://doi.org/10.1002/ehf2.14567

Internet

https://doi.org/10.1002/ehf2.14567

Similar Items